Plasma homovanillic acid and prolactin in Huntington's disease.
Dopaminergic activity is expected to be altered in patients with Huntington's disease (HD) and be related to factors like duration and severity of illness or patients' specific symptomatology like dementia, depression, or psychotic features. We assessed plasma homovanillic acid (pHVA) and plasma prolactin (pPRL), two correlates of dopaminergic activity, in 116 subjects with CAG repeats expansion in the HD gene, 26 presymptomatic (18 females) and 90 with overt symptomatology (43 females). Patients were evaluated using the Unified HD Rating Scale and the Total Functional Capacity Scale. Presence of dementia, depression, and psychotic features were also assessed. The age range of the patients was 22-83 years, duration of illness from 0.5 to 27 years, and CAG repeat number from 34 to 66. A group of 60 age and sex matched healthy subjects served as control group. Plasma PRL in subjects at risk and in neuroleptic-free patients, evaluated separately for males and females, did not differ from controls. Plasma HVA levels did not differ from controls in the group of presymptomatic subjects, but were significantly higher in the patients group. This increase was positively associated mainly with severity of illness and functional capacity of the patients, and not with presence of depression or dementia. Plasma HVA levels may be proven to be a peripheral index of disease progression. Reducing dopaminergic activity may have not only symptomatic, but also neuroprotective effects in HD.
Markianos
Manolis
M
Department of Neurology, Eginition Hospital, Athens University Medical School, Athens, Greece. markian@otenet.gr
Panas
Marios
M
Kalfakis
Nikos
N
Vassilopoulos
Dimitrios
D
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D000071058:Huntingtin Protein; D006816:Huntington Disease / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000235:genetics; D009687:Nuclear Proteins / Q000235:genetics; D011388:Prolactin / Q000097:blood*; D012720:Severity of Illness Index; D012737:Sex Factors; D019680:Trinucleotide Repeat Expansion; D055815:Young Adult
D014150:Antipsychotic Agents; C086055:HTT protein, human; D000071058:Huntingtin Protein; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D011388:Prolactin; D006220:Haloperidol; D004298:Dopamine; D006719:Homovanillic Acid